Article
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.
The Journal of pharmacology and experimental therapeutics - 1 Jan 1998
Ferguson R J, De Morais S M, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson G R, Sarich T C, Wright J M, Dayer P, Goldstein J A
Abstract excerpt
The 4'-hydroxylation of the S-enantiomer of the anticonvulsant drug mephenytoin exhibits a genetic polymorphism in humans. This polymorphism shows marked interracial heterogeneity, with the poor metabolizer (PM) phenotype representing 2 to 5% of Caucasian and 13 to 23% of Asian populations. Two d...
Topics
- Alleles
- Anticonvulsants
- Aryl Hydrocarbon Hydroxylases
- Codon
- Cytochrome P-450 CYP2C19
- Cytochrome P-450 Enzyme System
- Female
- Humans
- Male
- Mephenytoin
- Mixed Function Oxygenases
- Mutation